Nomura Holdings
SMMT icon

Nomura Holdings’s Summit Therapeutics SMMT Stock Holding History

Nomura Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$455K Buy
+24,000
New +$388K ﹤0.01% 1393
2025
Q4 		– Sell
-60,000
Closed -$1.24M – 2142
2025
Q3 		$1.24M Buy
+60,000
New +$1.46M ﹤0.01% 1323

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nomura Holdings's SMMT Position: Q1 2026 in Review

Nomura Holdings reduced its Summit Therapeutics (SMMT) stake by 42% in Q1 2026, selling an estimated $3.69M and leaving 313,981 shares worth $5.95M. The position accounts for 0.02% of the portfolio, ranked #590.

Nomura Holdings first reported a position in SMMT in Q1 2023 and has held it in 6 quarters since. The position peaked at $21.7M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Nomura Holdings held 313,981 shares of Summit Therapeutics worth $5.95M as of Q1 2026.
  • Nomura Holdings sold 228,253 Summit Therapeutics shares in Q1 2026, an estimated $3.69M.
  • Summit Therapeutics made up 0.02% of Nomura Holdings's portfolio in Q1 2026, its #590 holding.
  • Nomura Holdings first reported a position in Summit Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • Nomura Holdings's Summit Therapeutics position peaked at $21.7M in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.